Resistance to the antilipolytic effect of insulin (Adipo-IR) is increased in obese individuals with normal glucose tolerance (NGT), and in those with impaired glucose tolerance (IGT) and type 2 diabetes, according to a study published in Diabetes.
Resistance to the antilipolytic effect of insulin (Adipo-IR) is increased in obese individuals with normal glucose tolerance (NGT), and in those with impaired glucose tolerance (IGT) and type 2 diabetes, according to a study published in Diabetes.